BACKGROUNDEpidemiological estimates indicate a rising incidence of periprosthetic hip fractures. While native hip fractures are known to be a highly morbid condition, a significant body of research has led to improved outcomes and decreased complications following these injuries. Comparatively, little research has evaluated the relative morbidity and mortality of periprosthetic hip fractures. The purpose of this study was to compare the morbidity and mortality of periprosthetic vs native hip fractures.METHODSUsing the National Surgical Quality Improvement Program (NSQIP) database, 523 periprosthetic hip fractures were matched to native hip fractures using propensity scores. The 30-day rates of complications were compared using McNemar's test. A multivariate regression was then used to determine independent risk factors for mortality following periprosthetic fracture.RESULTSMortality was similar between groups (periprosthetic: 2.7% vs native: 3.4%; P = .49). Periprosthetic fractures exhibited a greater rate of overall (63.1% vs 38.6%; P < .001) and minor complications (59.1% vs 34.4%; P < .001). There was an increased rate of return to the operating room (7.8% vs 3.1%; P < .001) and blood transfusion in the periprosthetic group (54.9% vs 30.2%; P = .001). Age greater than 85 (odds ratio 9.21) and dependent functional status (odds ratio 5.38) were both independent risk factors for mortality following periprosthetic fracture.CONCLUSIONSWhile native hip fractures are known to be highly morbid, our findings suggest that periprosthetic hip fractures have a similar mortality with significantly higher short-term morbidity. Future research is warranted to better understand risk factors and prevention strategies for complications in this subset of patients.

01 Jun 2013·Clinical ChemistryQ1 · MEDICINE

Cobalt and Chromium Measurement in Patients with Metal Hip Prostheses

Q1 · MEDICINE

Article

Author: Hart, Alister J ; Estey, Mathew P ; Tower, Stephen S ; Van Der Straeten, Catherine ; Moyer, Thomas P ; Diamandis, Eleftherios P

Approximately 1 million metal-on-metal (MoM)6 hip prostheses have been implanted worldwide to alleviate pain, restore hip function, and improve overall quality of life. These implants contain femoral and acetabular bearing surfaces that are typically composed predominantly of cobalt (Co) and chromium (Cr). Although the majority of MoM hip replacements have been successful, multiple recent reports have documented markedly increased Co and Cr concentrations in the joint synovial fluid, periprosthetic tissue, blood, and even peripheral tissues of some patients with MoM hip prostheses. Consequently, concerns have been raised about the physiological consequences of metal release from MoM hip prostheses into the periprosthetic tissue and systemic circulation. Co and Cr concentrations in the serum and hip joint fluid correlate with the degree of MoM implant wear and are increased in individuals with an accumulation of metal debris in the periprosthetic tissue. Therefore, some scientists have suggested that Co and Cr concentrations be routinely measured during the management of patients with MoM hip prostheses. In this Q&A article, 4 experts provide their opinions on the use of MoM hip prostheses, the adverse biological consequences of metal release, and the clinical utility of Co and Cr measurements. They also discuss the methodology used to assess the concentration of these metal ions and provide insight into the many challenges associated with Co and Cr measurement. What are the advantages of MoM hip prostheses over other types of implants? Catherine Van Der Straeten: MoM was reintroduced as a bearing surface for hip arthroplasty to solve the problem of particle-induced osteolysis secondary to polyethylene wear. In vitro hip-simulator studies demonstrated much less volumetric wear and much smaller particles with MoM compared to metal-on-polyethylene (MoP). This finding was confirmed in vivo with high-carbon alloy MoM 28-mm and 32-mm total hip arthroplasty (THA). The use of larger-diameter femoral …

01 Dec 2010·Journal of Bone and Joint SurgeryQ2 · MEDICINE

A Case Report

Q2 · MEDICINE

Article

Author: Tower, Stephen S

Early failure of metal-on-metal hip arthroplasties is a current concern because tissue damage resulting from periprosthetic metallosis can compromise subsequent revision arthroplasty1,2. The United Kingdom’s Medicines and Healthcare products Regulatory Agency has advised that patients with metal-on-metal implants who have pain, prosthetic malposition, or implants that are known to have excessive failure rates should be evaluated with the measurement of serum cobalt. A serum cobalt level of >7 μg/L indicates possible periprosthetic metallosis3,4. A normal serum cobalt level is 0.19 μg/L, and 95% of those who are unexposed to cobalt have a value of 1 μg/L indicates excessive cobalt exposure, and levels of >5 μg/L are considered toxic6. In excess, cobalt blocks cellular metabolism and can damage multiple organs. Cobalt poisoning (cobaltism) from beer additives, industrial exposure, or medicinal use is well known. Cobaltism can result in tinnitus, vertigo, deafness, blindness, optic nerve atrophy, convulsions, headaches, peripheral neuropathy, cardiomyopathy, and hypothyroidism7,8. Including the two cases in the present report, there are at least six case reports of cobaltism related to arthroplasty implants (arthroprosthetic cobaltism)7,9-12. These four patients presented with combinations of deafness, blindness, cognitive decline, headaches, convulsions, fatigue, weakness, peripheral neuropathy, heart failure, and hypothyroidism. All of these patients had periprosthetic metallosis due to wear of steel femoral heads by ceramic, and all had a serum cobalt level of >60 μg/L. The two …

100 Deals associated with Anchorage Fracture & Orthopedic Clinic

100 Translational Medicine associated with Anchorage Fracture & Orthopedic Clinic

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 15 Nov 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Anchorage Fracture & Orthopedic Clinic

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 15 Nov 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing